NPC

http://www.npcnow.org/

Last activity: 01.10.2026

Active

Categories: CareDeliveryFinTechHealthTechIndustryMedtechResearchScience

The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.

Twitter

Mentions

Overview

Location

United States, District of Columbia, Washington

Mentions in press and media 26

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Sep 16, 2026	New Analysis Finds Manufacturers Account for Small Share of 'Social Surplus' Generated by Innovative Medicines	Researchers find manufacturers receive a minority of the net value innovative medicines create for society, with variation in how studies measure that share. WASHINGTON, DC, UNITED STATES, September 16, 2026 /EINPresswire.com/ -- A new lite...
Sep 15, 2026	New Research Finds China’s Share of First-Launched Medicines Surging, as Europe Lags and the U.S.’ Lead Weakens	The analysis, the first to examine two decades of global change in biopharmaceutical markets, shows shifts in the innovation landscape. WASHINGTON, DC, UNITED STATES, September 15, 2026 /EINPresswire.com/ -- New research from the National P...
Aug 19, 2026	Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits	National Pharmaceutical Council researchers examined questions about how these policies could affect patients, pharmacies, and providers. WASHINGTON, DC, UNITED STATES, August 19, 2026 /EINPresswire.com/ -- A new National Pharmaceutical Cou...
Aug 6, 2026	New in Health Affairs Forefront: 'Myths of Mandatory International Reference Pricing for Prescription Drugs'	A new article from the National Pharmaceutical Council includes evidence to dispel common myths about mandatory international reference pricing. WASHINGTON, DC, UNITED STATES, August 6, 2026 /EINPresswire.com/ -- A new Health Affairs Forefr...
Jul 22, 2026	Study Finds Medicare Part D Plans Likelier Than Commercial Plans to Restrict Drug Coverage in Competitive Drug Classes	Analysis of 2024-2026 formulary data found broader declines in coverage across competitive drug classes in Medicare Part D following implementation of the IRA This research finds that Medicare beneficiaries are losing coverage for certain d...
Jul 8, 2026	New Study Ties Increased Community Pharmacy Access to Lower Racial and Ethnic Disparities in Medication Use	Research underscores the importance of preserving pharmacy access & introduces a “disparity index” tool to measure pharmaceutical inequity. WASHINGTON, DC, UNITED STATES, July 8, 2026 /EINPresswire.com/ -- A new study published in Healt...
Jun 22, 2026	New Research Finds 340B Program Tied to Increased Hospital Assets and Administrative Salaries	Long-term 340B participation is linked to stronger financial assets, with much of the program’s recent growth flowing through child sites at wealthier hospitals WASHINGTON, DC, UNITED STATES, June 22, 2026 /EINPresswire.com/ -- New research...
May 14, 2026	New Research Identifies Steps to Improve Gene Therapy Contracting and Patient Access	A new NPC study in JMCP proposes consensus-based guidance to support sustainable payment approaches and improve equitable patient access to gene therapies. WASHINGTON, DC, UNITED STATES, May 14, 2026 /EINPresswire.com/ -- New research from ...
Mar 2, 2026	New Research Explores Gaps in Health Plan Implementation of FDA Label Revisions	Evidence suggests commercial health plans are more likely to delay specialty drug coverage decisions in response to FDA label expansions vs contractions. WASHINGTON, DC, UNITED STATES, March 2, 2026 /EINPresswire.com/ -- New research publis...
Oct 27, 2025	CMS Should Not Minimize Unmet Need in IRA’s Medicare DPNP	A new study from NPC & CU finds crucial elements of unmet medical need unaccounted for in current FDA guidelines which inform the IRA’s Medicare DPNP. WASHINGTON, DC, UNITED STATES, October 27, 2025 /EINPresswire.com/ -- Leaders at the ...
Oct 16, 2025	New NPC Analysis Illustrates How IRA’s Medicare Drug Price Negotiation Program May Reshape Pharmaceutical R&D Incentives	Study signals IRA’s widespread potential effects for long-term innovation incentives across disease states & disproportionate impact on small molecule drugs. WASHINGTON, DC, UNITED STATES, October 16, 2025 /EINPresswire.com/ -- A new an...
Sep 9, 2025	77% of Investors Say IRA's 'Pill Penalty' Disincentivizes Small Molecule Investments	Early signals of the IRA’s impact on pharmaceutical investor strategy include reduced investment in small molecules and favoring larger launch indications. WASHINGTON, DC, UNITED STATES, September 9, 2025 /EINPresswire.com/ -- Investors acr...
Sep 8, 2025	Study Links 340B Expansion With Higher ACA Premiums	Findings suggest an unintended consequence of 340B expansion is an association with ACA benchmark premium increases estimated at over $2 billion per year. WASHINGTON, DC, UNITED STATES, September 8, 2025 /EINPresswire.com/ -- The 340B Drug ...
Aug 8, 2025	New Study Reveals Significant Racial and Ethnic Disparities in Prescription Drug Utilization and Spending Across the US	Research highlights the need for local and condition-specific efforts to achieve equal access to medicine WASHINGTON, D.C., DC, UNITED STATES, August 8, 2025 /EINPresswire.com/ -- Significant racial and ethnic disparities exist in prescript...
Jul 8, 2025	Study Shows Critical Misalignment Between Health Plan Utilization Management & Clinical Guidelines for Specialty Drugs	Data from NPC and CEVR reveal utilization management is common even when clinical guidelines do not support its use. WASHINGTON, DC, UNITED STATES, July 8, 2025 /EINPresswire.com/ -- New research by the National Pharmaceutical Council (NPC)...
Jun 3, 2025	What the Growth of Utilization Management Says About the Future of Policy and Patient Access	A new Health Affairs Forefront primer examines the evolution of utilization management and its impact on patient access and policymaking for prescription drugs. WASHINGTON, DC, UNITED STATES, June 3, 2025 /EINPresswire.com/ -- More than 35 ...
May 13, 2025	New Studies Recommend Inclusion of Dynamic Inputs in Cost-Effectiveness Analyses to Better Reflect Drug Value Over Time	Cost-effectiveness models that exclude dynamic pricing likely underestimate a treatment’s benefits versus its costs to society WASHINGTON, DC, UNITED STATES, May 13, 2025 /EINPresswire.com/ -- Two new studies published in Value in Health un...
Mar 24, 2025	Whittington, Garrison, and Campbell: Challenges With Judging and Interpreting a Drug’s Launch Price (AJMC Commentary)	Challenges With Judging and Interpreting a Drug’s Launch Price A new publication suggests that decision makers take both a product lifetime view and a broader societal perspective when judging and rewarding value creation. WASHINGTON, DC, U...
Mar 20, 2025	What you need to know about copay accumulators and maximizers	New research in Health Affairs Forefront examines the rise of these cost-shifting programs, the impact on patients, and the policy environment surrounding them. WASHINGTON D.C., DC, UNITED STATES, March 20, 2025 /EINPresswire.com/ -- Well o...
Jun 27, 2024	The Harris Poll Announces Sponsorship of the 20th Anniversary Pharma PR & Communications Summit	The Stagwell (STGW) agency will share guidance for communicators during the 2024 election cycle NEW YORK, June 27, 2024 /PRNewswire/ -- The Harris Poll is once again sponsoring the Fierce Pharma PR & Communications Summit, the premier e...
Jan 23, 2023	What Prescription Drug Pricing Can Learn From Value-Based Care Models	During this past year, momentum has increased to make healthcare more accessible and affordable: Highlights in the realm of increasing accessibility to affordable care and streamlining user experiences include Amazon acquiring primary healt...
Oct 14, 2022	Monkeypox vaccine: a case study for real-world data	With health emergencies becoming more common, the world needs more efficient ways to test the safety and effectiveness of drugs, even if they haven’t yet completed the lengthy series of clinical trials the Food and Drug Administration usual...
Jul 25, 2018	Paying for therapies that cure: innovative solutions needed	The next generation of cancer therapies will be like nothing we have ever seen before: a single infusion of immune cells that have been trained to thrive inside the body, recognizing and destroying cancer cells. It feels like science fictio...
Aug 11, 2016	Nonprofit seeks to dispel ‘myths’ about how it assesses drug values	In the face of growing criticism over its efforts to place a value on new medicines, the Institute for Clinical and Economic Review is trying to strike back. Recently, the nonprofit took a conciliatory approach by soliciting suggestions for...
	Value assessment frameworks: Is there one “best” model?	By Dan Leonard, President and CEO, NPC Much of the biopharmaceutical industry this week is focused on the J.P. Morgan Healthcare Conference (JPM), where business leaders are investing in science and technologies with the potential to transf...

Reviews 0

FAQ about NPC

What has the press written about NPC?

Parsers VC has collected 26 articles mentioning NPC, among them “New Analysis Finds Manufacturers Account for Small Share of 'Social Surplus' Generated by Innovative Medicines” (Sep 16, 2026) and “New Research Finds China’s Share of First-Launched Medicines Surging, as Europe Lags and the U.S.’ Lead Weakens” (Sep 15, 2026).

Is NPC still active?

Yes, NPC is active; its latest activity on Parsers VC dates from Oct 1, 2026.